The highest DNA binding by 3-NBA in ES cells was observed at 10 μ

The highest DNA binding by 3-NBA in ES cells was observed at 10 μM after 24 h with 863 ± 74 adducts per 108 nucleotides (Fig. 3C). Interestingly, and in contrast to BaP, adduct levels for 3-NBA in MEFs were only 1.5-fold higher

(1266 ± 188 adduct per 108 nucleotides) under the same experimental conditions (Fig. 3D). DNA binding Selleckchem BMS-907351 was highest in MEFs at 10 μM after 48 h with 2478 ± 455 adducts per 108 nucleotides. Previously, in primary HUFs previously treated with 10 μM 3-NBA for 48 h, adduct levels were 680 ± 147 adducts per 108 nucleotides (Kucab et al., 2012). As 3-NBA is predominantly activated by NQO1 (Arlt et al., 2005), the expression of Nqo1 was studied in ES cells and MEFs by RT-PCR and revealed that Nqo1 mRNA expression increased in both cell types up to ∼60-fold; the induction was higher in MEFs than in ES cells ( Fig. 6C and D). This is in line with a previous study showing that Nqo1 protein levels were inducible in primary and immortal HUFs upon treatment with nitro-PAHs such as 1,8-dinitropyrene and 3-NBA ( Kucab et al., 2012). However, that study also showed that there was not a clear relationship between nitro-PAH-induced DNA adduct formation and the expression of Nqo1, suggesting

that other cytosolic nitroreductases such as xanthine oxidase might also contribute to the activation of nitro-PAHs like 3-NBA in HUFs ( Kucab et al., 2012). As shown in Fig. 5C and D, 3-NBA also induced Cyp1a1 mRNA expression, the induction in MEFs being manifoldly higher than in very ES cells. Other studies have Dasatinib price demonstrated the induction of Cyp1a1 protein levels in mouse Hepa1c1c7 cells after exposure to 3-NBA treatment ( Landvik et al., 2010) and in vivo in rats treated with 3-NBA ( Mizerovska et al., 2011, Stiborova et al., 2006 and Stiborova et al., 2008). The major activation pathway of AAI is

nitroreduction, cytosolic NQO1 being the most efficient activating enzyme while CYP1A-mediated demethylation contributes to AAI detoxification (Fig. 1C) (Stiborova et al., 2014a and Stiborova et al., 2013). Exposure to AAI resulted in loss of cell viability of both ES cells and MEFs (Fig. 2E and F). However, in contrast to 3-NBA which showed strong cytotoxicity in ES cells, AAI cytotoxicity was higher in MEFs. We therefore chose 20 μM and 50 μM AAI in MEFs while ES cells were treated with up to 100 μM for DNA adduct analysis by 32P-postlabelling (Fig. 3E and F). The AAI-induced adduct patterns in ES cells and MEFs were the same and identical to the patterns observed in kidney and ureter tissue of AAN patients (Gokmen et al., 2013 and Nortier et al., 2000). These adducts have previously been identified as 7-(deoxyadenosine-N6-yl)aristololactam I (dA-AAI; spot A1), 7-(deoxyguanosin-N2-yl)aristolactam I (dG-AAI; spot A2) and 7-(deoxyadenosin-N6-yl)aristolactam II (dA-AAII; spot A3) ( Bieler et al., 1997 and Schmeiser et al., 2014).

Comments are closed.